Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk

References

• Lannering B, Sandstrom PE, Holm S, Lundgren J, Pfeifer S, Samuelsson U, et al. Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984–2005. Acta Paediatr 2009;98:1620–7.
   PubMed Web of Science ®Google Scholar
• Brahme A, Agren AK. Optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1987; 26:377–85.
   PubMed Web of Science ®Google Scholar
• Chang JH, Lim JD, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using 11-C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys 2012;83:e691–6.
   Web of Science ®Google Scholar
• Berwouts D, Olteanu LA, Duprez F, Vercauteren T, De Gersem W, De Neve W, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: Initial results of the phase I clinical trial. Radiother Oncol 2013;107:310–6.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Vogelius IR, Maraldo MV, Munck af Rosenschöld P, Aznar MC, Kiil-Berthelsen A, et al. Life years lost – comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 2012;118:5432–40.
   PubMed Web of Science ®Google Scholar
• Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol 2008;10:745–51.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Vogelius IR, Bjork-Eriksson T, Munck af Rosenschöld P, Bentzen SM. Modeling freedom from progression for standard-risk medulloblastoma: A mathematical tumor control model with multiple modes of failure. Int J Radiat Oncol Biol Phys 2013;87:422–9.
   PubMed Web of Science ®Google Scholar
• Kim Y, Tome WA. Risk-adaptive optimization: Selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 2006;66:1528–42.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Tucker SL. Quantifying the position and steepness of radiation dose-response curves. Int J Radiat Biol 1997;71:531–42.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:946–58.
   PubMed Web of Science ®Google Scholar
• Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 2012;30:3187–93.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24:4202–8.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Munck af Rosenschöld P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol 2011;50:806–16.
   PubMed Web of Science ®Google Scholar
• ICRP. Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). ICRP Publication 92. Ann ICRP 2003;33.
   Google Scholar
• Goldwein JW, Radcliffe J, Johnson J, Moshang T, Packer RJ, Sutton LN, et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899–904.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 60:531–6.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Taguchi H, Sawamura Y, Ikeda J, Aoyama H, Fujieda K, et al. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system. Jpn J Clin Oncol 2008;38:486–92.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978–86.
   PubMed Web of Science ®Google Scholar
• Ashley DM, Merchant TE, Strother D, Zhou T, Duffner P, Burger PC, et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children’s Oncology Group study P9934. J Clin Oncol 2012;30:3181–6.
   PubMed Web of Science ®Google Scholar
• Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med 2010; 152:409–8.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408–14.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van Leeuwen FE. Are we improving the long-term burden of Hodgkin’s lymphoma patients with modern treatment?. Hematol Oncol Clin North Am 2007;21: 961–75.
   PubMed Web of Science ®Google Scholar